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Abstract
Background: Functional movement disorders are recognized as a ‘‘crisis’’ in neurology. We aimed to determine the rate of incidence of functional movement
disorder patients at a university outpatient neurology clinic in South Korea, and highlight the clinical and phenomenological characteristics.
Methods: Patients who were assessed by a movement disorders neurologist at a university hospital between March 2016 and May 2017 were screened for
functional movement disorders. Demographic and clinical data were reviewed, and the phenomenology of movements was studied.
Results: Of 321 patients evaluated for the chief complaint of a movement abnormality, approximately 10% (31 patients) were diagnosed with a functional
movement disorder. The female to male ratio was 7:1 (27 females to four males). The mean age at presentation was 53 years (standard error 3.6 years), and the
mean disease duration was 5 years (standard error 1.4 years). Sixty-one percent (19 out of 31 patients) had a past medical history of depression, anxiety, or other
psychiatric illnesses. Tremor and speech abnormalities were most prevalent (19 and 12 patients, respectively). Onset was reported to be abrupt in 14 patients (45%).
Thirteen (42%) patients were found to have improvement at a follow-up visit, 10 (32%) had no improvement, and eight (26%) were lost to follow-up.
Discussion: Functional movement disorders are not uncommon in the outpatient neurology clinic. Our results confirm that tremor is the most frequent movement
occurring in functional movement disorders, and the most commonly affected body parts were found to be the upper and lower extremities. Speech was also found
to be frequently involved (39%). Patients with no improvement at follow-up had longer mean disease duration (6.2 years), consistent with previous observations that
prolonged symptom duration is associated with poor clinical outcome. Our study results obtained from a Korean population suggest that previous observations on
functional movement disorders from other regions hold true in Eastern Asia.
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Introduction
Functional, often referred to as psychogenic, movement disorders
are those that are presumed to be attributable to a psychological cause.1,2
Contrary to what the term ‘‘psychogenic’’ implies, the movements are
regarded involuntary.3 The movements occurring in functional move-
ment disorders may vary in phenomenology, and more than one type of
movement may occur in a single patient. Various body parts may be
affected, and speech may also be involved.4–6
Historically, functional movement disorders have been referred to
by different names such as hysteria or conversion disorder. Although
the term psychogenic is currently the most widely used term, it has
been proposed that the term functional movement disorder should be
used, for both scientific and practical reasons.1,7 Functional movement
disorders are common, and represent approximately 3% of movement
disorder clinic visits.6,8 The diagnosis of functional movement disorder
is typically a clinical one.9 While several diagnostic criteria have been
proposed, these are often not used, and for the identification of posi-
tive signs for a functional movement disorder such as distractability,
entrainability (e.g., tremor entrainability), and variability appears to be
more practical in clinical practice.2,10,11
To date, several clinic-based studies on the epidemiology of func-
tional movement disorders have been reported.5,8,12–14 These studies
have been mostly conducted in the United States and Europe, and
knowledge of the epidemiology and clinical characteristics of this
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patient population in other regions of the world such as Eastern Asia
is lacking. A recent study of clinical decision-making in functional
movement disorders reached the conclusion that experts rely heavily
on clinical assessment to make a diagnosis.9 This clinical assessment
was found to be predominantly based on the visual first impression of
the patient, neurological examination, and medical history. We aimed
to conduct an epidemiological, phenomenological, and clinical investi-
gation of functional movement disorders in a university clinic, to
provide information relevant to the epidemiology and clinical char-
acteristics of this disorder found in a functional movement disorders
population in Eastern Asia.
Methods
Subjects
The electronic medical records of patients with the chief complaint
of a movement abnormality seen at the outpatient neurology clinic of
Dongguk University Ilsan Hospital between March 2016 and May
2017 were reviewed. Clinical and demographic features were manually
extracted from the electronic medical record system into a movement
disorder database. In case of missing information, clarification was
sought during routine follow-up visits to the clinic. All patients under-
went an interview and examination of their movements by a neuro-
logist trained in movement disorders (J.E.P.). Patients who met the
criteria for a functional movement disorder were identified. These
criteria include variability, distractibility, and entrainability of the
involuntary movements. The medical history was carefully reviewed.
Movements of patients who were willing to be videotaped were recorded
on the day of their initial visit. The diagnosis of a functional movement
disorder was relayed to the patient by the examining neurologist at the
first or subsequent visit.
Results
Demographics
A total of 321 patients were identified, of which approximately 10%
(31 patients) were diagnosed with a functional movement disorder.
The female to male ratio was 6.8:1 (27 females to four males). The age
of onset ranged from 17 to 91 years and the mean age at presentation
was 53 years (standard error 3.6 years). The mean disease duration was
5 years (standard error 1.4 years) and the mean follow-up period was
5 months (standard error 1.8 months). Fifty-eight percent (18 out of
31 patients) had a past medical history of depression, anxiety, or other
psychiatric illnesses. The most commonly reported psychiatric morbi-
dity was depression (17 out of 31 patients). Nineteen (61%) patients
acknowledged feeling ‘‘stressed’’ in their daily lives, six patients denied
experiencing such feelings, five did not provide the examiner with a
clear answer, and one patient was cognitively impaired because of
dementia and thus was not able to give a response. One patient
reported a history of sexual abuse in her teenage years. Others
reported stressful events such as a family member’s death, a spouse’s
business debt, misbehavior of a child, career and academic difficulties,
and trouble with friends or family members. One patient reported a
positive family history of a movement disorder, which was confirmed
to be functional by the examining neurologist (J.E.P.) at a subsequent
visit accompanied by the affected family member. Socioeconomic status
was not an aspect that was probed because of concern for sensitivity of
patients and potential reluctance to provide such details.
Clinical course
Onset was noted to be abrupt (defined as symptom development
within a few days) in 15 patients (48%). Thirteen (42%) out of 31 patients
were found to have improvement at a follow-up visit, 10 patients (32%)
with no improvement, and eight patients (26%) were lost to follow-up.
Lost to follow-up was defined as no more than a total of two clinic visits.
The subgroup of patients who experienced improvement were found to
have a mean disease duration of 2.3 years (standard error 1 year), whereas
those who did not experience improvement at follow-up had a mean
disease duration of 6.2 years (standard error 2.7 years), and those lost to
follow-up 7.9 years (standard error 5.2 years) (Figure 1). For patients who
acknowledged depressed mood or high levels of stress, medication was
offered as a treatment option and 12 patients (39%) were started on an
antidepressant (escitalopram or duloxetine). Seven of the 12 patients were
found to have improvement of their movement symptoms, and of the five
patients that did not improve, two discontinued the prescribed antidepres-
sant because of side effects (somnolence, fatigue).
Movement characteristics
In 21 patients (68%), more than one body part was affected (the
voice was also considered to be an independent body part). Seven
patients (23%) were found to have more than one type of movement
(tremor, myoclonus, or speech involvement). On the day of their initial
visit, 19 patients (61%) were found to have tremor, 10 patients (32%)
abnormal speech or voice, seven patients (23%) myoclonus, and five
patients (16%) gait difficulty (Supplementary Table 1). Gait abnorm-
ality was the least common but varied widely in phenomenology.
Gait abnormalities included ataxic gait, scissoring gait, spastic gait, and
dromedary gait (characterized as gradually increasing forward flexion
of the lumbar spine on walking).
The body parts most commonly affected were the bilateral upper
(11 patients, 36%) and lower extremities (11 patients, 36%). The head
was the next most commonly involved body part (10 patients, 32%).
Other affected body parts included the voice, eyes, face, jaw, shoulders,
trunk, and abdomen. Twelve patients (39%) were found to have affected
speech or voice. Abnormalities included stuttering,3 dysphonia,3
infantile speech,3 hypernasality,2 dysarthria,2 and hypophonia,1 with
some patients having a combination of different speech or voice abnor-
malities. Nine of these patients were found to have concurrent symptoms
of involuntary movements. The mean disease duration of patients with
speech or voice abnormalities as the chief complaint was 4.2 years
(standard error 2.9 years).
Diagnosis
All patients were given the diagnosis of a functional movement
disorder at their first or subsequent visit by a neurologist trained in
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movement disorders (J.E.P.). When the diagnosis was delivered, certain
features of their movements supporting the diagnosis of a functional
movement disorder such as distractibility, entrainability, and vari-
ability were shared. All but one patient (case 8, 17-year-old female with
functional gait) were found to be fully receptive of the diagnosis.
Prognosis of the disorder was also discussed clearly and candidly,
which was generally relayed as one or more of the following messages:
‘‘the hardware, which is the nervous system itself, is fine, but the
software is malfunctioning that may be due to psychological factors or
stress’’, and that ‘‘generally, there is a better chance of recovery for
patients who are receptive of the diagnosis’’.
Discussion
Functional movement disorders are not uncommon in the out-
patient neurology clinic. We found that the proportion of psychogenic
movement disorders in our patient population (10%) was higher than
that noted in previous studies, ranging from 3% to 5%.8,13 This may
be relative to the fact that the evaluation was conducted by a neuro-
logist trained in movement disorders keen to identify positive diagnostic
features of this disorder. We found a female predominance (female/
male 6.8:1), and although the age of onset ranged widely (17–91 years),
the median age of onset was 54.5 years, falling into the working age
population defined as those aged 15–64 years (Organization for Eco-
nomic Cooperation and Development data, https://data.oecd.org/
pop/working-age-population.htm). In our patient population, the most
commonly affected body parts were the upper and lower extremities,
and speech was also frequently involved, at 32%. We speculate that
these patients are likely impacted in their daily activities, although this
was not quantified in the current study. Given that the median age of
onset is working age, a future study to quantify the level of disability
may be worthwhile as the disorder may affect not only the affected
individual, but also extend to having an impact on society.
Our study results reveal that the subgroup of patients who were
found to improve at a subsequent clinic visit had shorter mean disease
duration, while the subgroup of patients whose clinical outcome remained
unchanged and those lost to follow-up had longer mean disease
duration. This further highlights symptom duration as an important
prognostic factor in functional movement disorders. Our results there-
fore support previous observations that prolonged symptom duration is
associated with poor prognosis.5,7,15 We also confirmed previous
reports of tremor as the most frequent movement occurring in func-
tional movement disorders.8
In our patient population, the types of psychiatric comorbidity were
found to be mostly depression and anxiety, and prevalence was 59%,
which is comparable to that described in previous reports.13 Onset of
symptoms was found to be abrupt in 46%, whereas another study
reported this to be 62%. Of note, 12 patients who did not have a
previous psychiatric diagnosis but acknowledged depressed mood or
high levels of stress were started on an antidepressant, and seven of
these patients (58%) improved. While this could be a placebo effect
and the clinical course should be followed, it is possible that the
improvement is relevant to medical treatment of underlying depression
or anxiety. However, the present results are limited in that we were
unable to perform a standardized psychiatric evaluation; further, while
we found a subset of patients to acknowledge depressed mood or stres-
sors, it is still possible that psychiatric comorbidities were underreported.
In our study, the diagnosis was based on the visual first impression,
neurological examination of the patient with emphasis on searching for
Figure 1. Mean Disease Duration by Clinical Outcome. The mean disease duration for the subgroups is shown. Patients who were seen at follow-up and
found to exhibit improvement had mean disease duration of 2.3 years, whereas those who had no improvement or were lost to follow-up had mean disease duration
of 6.2 years and 7.9 years, respectively.
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the presence of positive signs, and medical history, as a previous study
has shown that these are most important when establishing a diagnosis
of a functional movement disorder.9 We chose to disclose the diagnosis
to the patient clearly, but using a sympathetic approach. It is well
known that when the patient is given the vague impression of being a
‘‘medical mystery’’, this may result in further unnecessary medical
investigation and prolonged symptom duration. In our study popula-
tion, the diagnosis of a functional movement disorder was shared with
the patient at the first or subsequent visit, and all but one patient
appeared to be receptive of the diagnosis. However, it is possible that
the eight patients lost to follow-up may have been only outwardly
receptive of the diagnosis and possibly sought further evaluation
elsewhere.
Our study is not without limitations. As this was a retrospective
study based on outpatient encounters, our findings were limited because
some patients were lost to follow-up. However, we are cautious to view
this as a mere limitation, as it may be another facet of this disorder
associated with patients’ reluctance to accept the diagnosis. Our study
findings show that patients lost to follow-up had the longest mean
disease duration (7.9 years) of the three subgroups previously mentioned,
and it is possible that this subgroup chose not to follow up in order to
pursue further diagnostic evaluation elsewhere. Another limitation of
our study is that patients did not receive a standardized psychiatric
evaluation that would have allowed for a more detailed assessment of
potential psychiatric comorbidities. While some patients revealed such
pertinent psychiatric history to the neurologist, it is possible that others
may have chosen not to share such information. Our study findings
were also based on relatively brief outpatient encounters that are
usually not conducive to sharing private information such as sexual,
emotional or physical trauma. Therefore, it is possible that such
factors considered to be relevant in this disorder were underreported.
In addition, information on patients’ quality of life or disability was not
obtained in a standardized manner: such information would certainly
be valuable for understanding the impact of this disorder. Other
limitations of this study are that the duration of follow-up was not
consistent in all subjects, and patients were evaluated at our institution
by a single neurologist trained in movement disorders. Many of these
limitations however reflect the real-life setting, as it is common in many
countries (particularly in Asia) for clinic visits to be brief and follow-up
periods to vary. To date, there are only two studies from Korea for
which the text is not available in English, and no studies on this patient
population from other Eastern Asian countries.
There have been advances in understanding the neurophysiology
of functional movement disorders. Past studies have found that the
involuntary movements in patients with functional disorders utilize the
voluntary motor system, as demonstrated by the presence of the Bereit-
schaftspotential (also called movement-related cortical potential).16–19
More recent studies utilizing functional magnetic resonance imaging
(fMRI) of the brain have found that decreased functional connectivity
of brain regions involved in the sense of self-agency underlies patients’
experience of lack of voluntariness.20,21 The loss of sensory attenuation
(the decrease in the gain of the sensory consequences of one’s own
actions) has also been observed, which has been found to correlate with
the loss of self-agency.22 While these investigations are important for
the enhancement of our understanding of the physiology of this
disorder, such testing is usually not feasible to perform in a routine
clinical setting, and the diagnosis of a functional movement disorder is
often made clinically.
Despite the increasing interest in this disorder and relevant neuro-
physiological investigation, treatment options are still limited. Positive
results have been noted with physical therapy/rehabilitation, including
some randomized trials.15,23–26 Important factors indicative of a better
prognosis include acceptance of the diagnosis by the patient, identifi-
cation and management of concurrent psychiatric disorders and psycho-
logical stressors, and the maintenance of a supportive social network.27
Therefore, while there is no definitive treatment for this disorder,
working with the patient to facilitate acceptance of the diagnosis as well
as addressing associated psychiatric issues and utilizing physical
therapy when feasible are essential to recovery and a better prognosis.
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